id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1245-0008,FDA,FDA-2012-E-1245,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-10T04:00:00Z,2015,3,2015-03-10T04:00:00Z,,2015-03-10T12:32:17Z,,0,0,0900006481a37042
FDA-2012-E-1245-0007,FDA,FDA-2012-E-1245,"Letter from U.S. Patent and Trademark Office to Finnegan, Henderson, Farabow, Garrett & Dunner LLP",Other,Letter(s),2014-07-16T04:00:00Z,2014,7,2014-07-16T04:00:00Z,,2014-07-16T18:50:02Z,,0,0,09000064817b2214
FDA-2012-E-1245-0006,FDA,FDA-2012-E-1245,"Determination of Regulatory Review Period for Purposes of Patent
Extension; MENHIBRIX",Notice,General Notice,2014-05-28T04:00:00Z,2014,5,2014-05-28T04:00:00Z,,2014-05-28T14:16:06Z,2014-12294,0,0,0900006481719604
FDA-2012-E-1245-0005,FDA,FDA-2012-E-1245,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-12T04:00:00Z,2014,5,2014-05-12T04:00:00Z,,2014-05-12T17:02:01Z,,0,0,09000064816f1b6b
FDA-2012-E-1245-0004,FDA,FDA-2012-E-1245,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2014-04-08T04:00:00Z,2014,4,2014-04-08T04:00:00Z,,2014-04-09T01:54:58Z,,0,0,09000064816a9f6b
FDA-2012-E-1245-0003,FDA,FDA-2012-E-1245,FDA/CDER  to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-03-04T05:00:00Z,2013,3,2013-03-04T05:00:00Z,,2013-03-04T14:40:35Z,,0,0,090000648121672e
FDA-2012-E-1245-0001,FDA,FDA-2012-E-1245,"The Henry M. Jackson Foundation for the Advancement of Military Meicine (Finnegan, Henderson, et al) - Patent Extension Application",Other,Application,2012-12-31T05:00:00Z,2012,12,2012-12-31T05:00:00Z,,2012-12-31T21:46:33Z,,0,0,09000064811a0ce5
FDA-2012-E-1245-0002,FDA,FDA-2012-E-1245,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-31T05:00:00Z,2012,12,2012-12-31T05:00:00Z,,2012-12-31T21:46:33Z,,0,0,09000064811a0ce7